Discovery of key biomarkers in tourette syndrome by network pharmacology

Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research. The ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target ne...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 15; p. 1397203
Main Authors Zhao, Jiali, Bai, Xiaohong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.09.2024
Subjects
immune infiltration
LASSO regression and SVM algorithm
network pharmacology
Pharmacology
tourette syndrome
Yangxue Xifeng decoction
Yangxue Xifeng decoction
tourette syndrome
immune infiltration
network pharmacology
LASSO regression and SVM algorithm
Online AccessGet full text

Cover

Abstract Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research. The ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using "RcisTarge". 127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. and were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in and were enriched. Furthermore, remarkable correlation was found between and levels and other TS-related genes such as and . and and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.
AbstractList Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research. The ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using "RcisTarge". 127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. and were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in and were enriched. Furthermore, remarkable correlation was found between and levels and other TS-related genes such as and . and and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.
Background Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research. Methods The ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using “RcisTarge”. Results 127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. OPRM1 and VIM were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in OPRM1 and VIM were enriched. Furthermore, remarkable correlation was found between OPRM1 and VIM levels and other TS-related genes such as MAPT and MAPT . Conclusion OPRM1 and MAPT, and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.
BackgroundYangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research.MethodsThe ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using “RcisTarge”.Results127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. OPRM1 and VIM were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in OPRM1 and VIM were enriched. Furthermore, remarkable correlation was found between OPRM1 and VIM levels and other TS-related genes such as MAPT and MAPT.ConclusionOPRM1 and MAPT, and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.
Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research.BackgroundYangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research.The ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using "RcisTarge".MethodsThe ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using "RcisTarge".127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. OPRM1 and VIM were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in OPRM1 and VIM were enriched. Furthermore, remarkable correlation was found between OPRM1 and VIM levels and other TS-related genes such as MAPT and MAPT.Results127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. OPRM1 and VIM were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in OPRM1 and VIM were enriched. Furthermore, remarkable correlation was found between OPRM1 and VIM levels and other TS-related genes such as MAPT and MAPT.OPRM1 and MAPT, and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.ConclusionOPRM1 and MAPT, and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.
Author Zhao, Jiali
Bai, Xiaohong
AuthorAffiliation 2 Harbin Hospital of Traditional Chinese Medicine , Harbin , Heilongjiang , China
3 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine , Shenyang , China
1 Liaoning University of Traditional Chinese Medicine , Shenyang , China
AuthorAffiliation_xml – name: 3 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine , Shenyang , China
– name: 1 Liaoning University of Traditional Chinese Medicine , Shenyang , China
– name: 2 Harbin Hospital of Traditional Chinese Medicine , Harbin , Heilongjiang , China
Author_xml – sequence: 1
  givenname: Jiali
  surname: Zhao
  fullname: Zhao, Jiali
  organization: Harbin Hospital of Traditional Chinese Medicine, Harbin, Heilongjiang, China
– sequence: 2
  givenname: Xiaohong
  surname: Bai
  fullname: Bai, Xiaohong
  organization: Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39318779$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1PJCEQhslGs37-gT1sOHqZESiGhtPGuH4lJl70TGimGNvpbmahx03_exlnNMoFAlUPb-o5Int97JGQX5xNAbQ5D6tnl6aCCTnlYCrB4Ac55ErBxGgu9r6cD8hpzi-sLDAGlPxJDsAA11VlDsnt3yb7-IpppDHQJY60bmLn0hJTpk1Ph7hOOAxI89jPU-yQ1iPtcfgf05JuInTOxzYuxhOyH1yb8XS3H5On66vHy9vJ_cPN3eXF_cQDU8PEKI_CIK-Qce5mXAvnnQ-BzbwEPQPhg3aVlhKlDkExlArdPAjtS3zNEY7J3ZY7j-7FrlJTwo42usa-X8S0sC4NjW_R1qiDn0kNTmrJEE0lA8fgWBCqNkwV1p8ta7WuO5x77Ifk2m_Q7y9982wX8dVyLkWZpy6Esx0hxX9rzIPtyjyxbV2PcZ0tcGYkFDmslIptqU8x54Th8x_O7EapfVdqN0rtTmlp-v014WfLh0B4AzOGoQs
Cites_doi 10.1016/j.neubiorev.2013.03.012
10.1016/j.heliyon.2023.e12874
10.1016/j.brainres.2014.04.027
10.1002/mds.27519
10.3390/ijms24021428
10.1007/s13311-020-00914-6
10.5334/tohm.464
10.1007/s11655-019-3064-0
10.3389/fgene.2021.658323
10.1016/j.bj.2022.04.004
10.1186/s13059-022-02755-2
10.1016/j.bj.2022.01.008
10.3390/ijms23010090
10.1186/s13041-015-0133-y
10.1542/peds.2022-059574
10.1080/13546805.2020.1760812
10.1016/j.biopha.2020.111198
10.1016/j.bbi.2022.07.006
10.3389/fnins.2021.654238
10.1038/s41380-019-0600-4
10.1016/j.compbiomed.2021.104636
10.1038/s41537-024-00156-7
10.1155/2022/5080282
10.1038/nrg1379
10.3389/fpsyt.2020.00774
10.1016/j.nicl.2019.101998
10.3389/fneur.2020.567407
10.1038/s41380-022-01880-5
10.3390/ijms22020853
10.1016/B978-0-323-98817-9.00002-8
10.5409/wjcp.v7.i1.36
10.1212/WNL.0000000000007467
10.1016/j.jep.2022.115876
10.1016/j.braindev.2020.01.002
10.1007/s40263-018-0559-8
10.1097/WCO.0000000000000575
10.1016/j.biopsych.2004.12.004
10.1016/j.biopsych.2014.07.018
10.1523/JNEUROSCI.0150-11.2011
ContentType Journal Article
Copyright Copyright © 2024 Zhao and Bai.
Copyright © 2024 Zhao and Bai. 2024 Zhao and Bai
Copyright_xml – notice: Copyright © 2024 Zhao and Bai.
– notice: Copyright © 2024 Zhao and Bai. 2024 Zhao and Bai
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fphar.2024.1397203
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals at publisher websites
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ - Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Zhao and Bai
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_be8fc5483a4840ee974f1efa0f26b906
10_3389_fphar_2024_1397203
39318779
Genre Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c306t-96ce29e17e011a5182acacff05c438532cf8a7844e48ff60e46eadf28c00381e3
IEDL.DBID RPM
ISSN 1663-9812
IngestDate Tue Oct 22 15:04:34 EDT 2024
Wed Sep 25 09:19:51 EDT 2024
Sat Oct 26 02:12:47 EDT 2024
Thu Sep 26 20:56:29 EDT 2024
Sat Nov 02 12:23:17 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Yangxue Xifeng decoction
tourette syndrome
immune infiltration
network pharmacology
LASSO regression and SVM algorithm
Language English
License Copyright © 2024 Zhao and Bai.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c306t-96ce29e17e011a5182acacff05c438532cf8a7844e48ff60e46eadf28c00381e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Wenqiang Cui, Chinese Academy of Sciences (CAS), China
Edited by: Sajjad Gharaghani, University of Tehran, Iran
Félix Javier Jiménez-Jiménez, Hospital Universitario del Sureste, Spain
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420008/
PMID 39318779
PQID 3109432030
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_be8fc5483a4840ee974f1efa0f26b906
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11420008
proquest_miscellaneous_3109432030
crossref_primary_10_3389_fphar_2024_1397203
pubmed_primary_39318779
PublicationCentury 2000
PublicationDate 2024-09-10
PublicationDateYYYYMMDD 2024-09-10
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-10
  day: 10
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2024
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Liu (B32) 2020; 11
Rizzo (B43) 2015; 8
Kim (B26) 2018
Hsu (B23); 22
Set (B45) 2021
Tchalova (B48) 2021; 26
Depienne (B10) 2019; 9
He (B21) 2004; 5
Billnitzer (B2) 2020; 17
Leckman (B28) 2005; 57
Hartmann (B20) 2018
Martino (B35) 2015
Xiao (B52) 2017
Liu (B31) 2021; 12
Domènech (B11) 2021
Martino (B34) 2020; 11
Ogundele (B38) 2018; 7
Hsu (B22); 22
Efron (B14) 2018
Pringsheim (B40); 92
Seideman Mf Fau - Seideman (B44) 2020
Tsetsos (B49) 2024; 18
Niu (B37) 2022
Cormier-Dequaire (B8) 2018; 33
Felling (B16) 2011; 31
Shang (B46) 2023; 302
Lin (B30) 2022
Kattner (B25) 2022
Dec. Erga (B9) 2018; 15
Chou (B7) 2023; 9
Szejko (B47) 2022
Brady (B3) 2022
Johnson (B24) 2023
Pringsheim (B41)
Chen (B6) 2020
Gilbert (B19) 2024
Bhikram (B1) 2022; 105
Eapen (B12)
Kuret (B27) 2022; 23
Xi (B51) 2022; 2022
First (B17) 2012
Ghafouri-Fard (B18) 2021; 135
Luo (B33) 2020; 26
B53
Nilles (B36) 2023
Zingale (B54) 2021; 23
Widomska (B50) 2023; 24
Lennington (B29) 2016; 372
Buse (B4) 2013
Eapen (B13)
Paschou (B39) 2013
Elamin (B15) 2013
Cavanna (B5) 2020
Ramkiran (B42) 2019; 24
References_xml – start-page: 1873
  year: 2013
  ident: B4
  article-title: Neuromodulation in Tourette syndrome: dopamine and beyond
  publication-title: Neurosci Biobehav Rev
  doi: 10.1016/j.neubiorev.2013.03.012
  contributor:
    fullname: Buse
– volume: 9
  start-page: 2405
  year: 2023
  ident: B7
  article-title: Emerging therapies and recent advances for Tourette syndrome
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2023.e12874
  contributor:
    fullname: Chou
– volume-title: Brain, Behavior, and Immunity
  year: 2015
  ident: B35
  article-title: The role of immune mechanisms in Tourette syndrome
  doi: 10.1016/j.brainres.2014.04.027
  contributor:
    fullname: Martino
– start-page: 131
  volume-title: International review of movement disorders
  year: 2022
  ident: B47
  article-title: Chapter Four - update and recent progress in the neurobiology of Tourette syndrome
  contributor:
    fullname: Szejko
– volume: 33
  start-page: 1878
  year: 2018
  ident: B8
  article-title: Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease
  publication-title: Electronic
  doi: 10.1002/mds.27519
  contributor:
    fullname: Cormier-Dequaire
– year: 2021
  ident: B11
  article-title: Genetic architecture of Tourette syndrome: Our current understanding
  publication-title: J. Genet. Psychol.
  contributor:
    fullname: Domènech
– volume: 24
  start-page: 1428
  year: 2023
  ident: B50
  article-title: Molecular andscape of ourette's isorder
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms24021428
  contributor:
    fullname: Widomska
– volume: 17
  start-page: 1681
  year: 2020
  ident: B2
  article-title: Current anagement of ics and ourette yndrome: ehavioral, harmacologic, and urgical reatments
  publication-title: Neurotherapeutics
  doi: 10.1007/s13311-020-00914-6
  contributor:
    fullname: Billnitzer
– volume: 9
  start-page: 2160
  year: 2019
  ident: B10
  article-title: Association of are enetic ariants in pioid eceptors with ourette yndrome
  publication-title: LID
  doi: 10.5334/tohm.464
  contributor:
    fullname: Depienne
– volume: 26
  start-page: 72
  year: 2020
  ident: B33
  article-title: Network harmacology in esearch of Chinese edicine ormula: ethodology, pplication and rospective
  publication-title: Chin. J. Integr. Med.
  doi: 10.1007/s11655-019-3064-0
  contributor:
    fullname: Luo
– volume: 12
  start-page: 658323
  year: 2021
  ident: B31
  article-title: Discovery and alidation of ey iomarkers ased on mmune nfiltrates in Alzheimer's isease
  publication-title: Front Genet
  doi: 10.3389/fgene.2021.658323
  contributor:
    fullname: Liu
– volume-title: Neuroscience and Biobehavioral Reviews
  year: 2022
  ident: B25
  article-title: What makes tics tick? Insights into tourette syndrome
  doi: 10.1016/j.bj.2022.04.004
  contributor:
    fullname: Kattner
– year: 2013
  ident: B15
  article-title: Immune dysfunction in Tourette syndrome
  publication-title: J. Immunol. Res
  contributor:
    fullname: Elamin
– volume-title: Practice guideline recommendations summary: reatment of tics in people with Tourette syndrome and chronic tic disorders
  ident: B41
  contributor:
    fullname: Pringsheim
– volume: 23
  start-page: 191
  year: 2022
  ident: B27
  article-title: Positional motif analysis reveals the extent of specificity of protein-RNA interactions observed by CLIP
  publication-title: Genome Biol
  doi: 10.1186/s13059-022-02755-2
  contributor:
    fullname: Kuret
– ident: B12
  article-title: Social impact and quality of life in Tourette syndrome
  publication-title: J. Behav. Health
  contributor:
    fullname: Eapen
– volume-title: Journal of Medical Genetics
  year: 2022
  ident: B30
  article-title: Current understanding of the genetics of Tourette syndrome
  doi: 10.1016/j.bj.2022.01.008
  contributor:
    fullname: Lin
– start-page: 0065
  volume-title: Traditional Chinese edicine (TCM) therapy
  year: 2017
  ident: B52
  contributor:
    fullname: Xiao
– ident: B13
  article-title: Tourette syndrome, co-morbidities, and quality of life
  publication-title: Clin. Psychol. Rev
  contributor:
    fullname: Eapen
– volume: 23
  start-page: 90
  year: 2021
  ident: B54
  article-title: MiR-155: n mportant egulator of euroinflammation
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23010090
  contributor:
    fullname: Zingale
– volume: 8
  start-page: 44
  year: 2015
  ident: B43
  article-title: Circulating miRNAs profiles in Tourette syndrome: molecular data and clinical implications
  publication-title: Mol
  doi: 10.1186/s13041-015-0133-y
  contributor:
    fullname: Rizzo
– start-page: e2022059574
  year: 2024
  ident: B19
  article-title: Innovative therapies for Tourette syndrome: a trial
  publication-title: Pediatrics
  doi: 10.1542/peds.2022-059574
  contributor:
    fullname: Gilbert
– start-page: 1464
  year: 2020
  ident: B5
  article-title: The cognitive neuropsychiatry of Tourette syndrome
  publication-title: Cogn Neuropsychiatry
  doi: 10.1080/13546805.2020.1760812
  contributor:
    fullname: Cavanna
– volume: 135
  start-page: 111198
  year: 2021
  ident: B18
  article-title: An update on the role of miR-124 in the pathogenesis of human disorders
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2020.111198
  contributor:
    fullname: Ghafouri-Fard
– volume: 105
  start-page: 237
  year: 2022
  ident: B1
  article-title: Neutrophil-lymphocyte ratios as inflammatory biomarkers in psychiatric patients
  publication-title: Behav Immun
  doi: 10.1016/j.bbi.2022.07.006
  contributor:
    fullname: Bhikram
– volume: 15
  start-page: 1664
  year: 2018
  ident: B9
  article-title: Dopaminergic and pioid athways ssociated with mpulse ontrol isorders in Parkinson's isease
  publication-title: Front. Neurosci
  doi: 10.3389/fnins.2021.654238
  contributor:
    fullname: Dec. Erga
– volume: 26
  start-page: 1476
  year: 2021
  ident: B48
  article-title: Variation in the μ-opioid receptor gene (OPRM1) and experiences of felt security in response to a romantic partner's quarrelsome behavior
  publication-title: Mol Psychiatry
  doi: 10.1038/s41380-019-0600-4
  contributor:
    fullname: Tchalova
– volume-title: Pharmacological Research
  year: 2022
  ident: B37
  article-title: Network pharmacology-based analysis of the anti-hyperglycemic active ingredients and experimental validation
  doi: 10.1016/j.compbiomed.2021.104636
  contributor:
    fullname: Niu
– volume: 18
  year: 2024
  ident: B49
  article-title: Synaptic processes and immune-related pathways implicated in Tourette syndrome
  publication-title: Transl. Psychiatry.
  doi: 10.1038/s41537-024-00156-7
  contributor:
    fullname: Tsetsos
– start-page: 1474
  year: 2023
  ident: B24
  article-title: Tourette syndrome: clinical features
  contributor:
    fullname: Johnson
– volume: 2022
  start-page: 1741
  year: 2022
  ident: B51
  article-title: Potential lasma etabolic iomarkers of ourette yndrome iscovery ased on ntegrated ontargeted and argeted etabolomics creening lasma etabolic iomarkers of TS
  publication-title: Evid Based Complement Alternat Med
  doi: 10.1155/2022/5080282
  contributor:
    fullname: Xi
– year: 2018
  ident: B14
  article-title: Tics and Tourette syndrome
  publication-title: Neuropsychiatr. dis. treat
  contributor:
    fullname: Efron
– volume: 5
  start-page: 522
  year: 2004
  ident: B21
  article-title: MicroRNAs: small RNAs with a big role in gene regulation
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg1379
  contributor:
    fullname: He
– volume: 11
  start-page: 1664
  year: 2020
  ident: B32
  article-title: Current tatus, iagnosis, and reatment ecommendation for ic isorders in China
  publication-title: Front. Psychiatry
  doi: 10.3389/fpsyt.2020.00774
  contributor:
    fullname: Liu
– volume: 24
  start-page: 101998
  year: 2019
  ident: B42
  article-title: Alterations in basal ganglia-cerebello-thalamo-cortical connectivity and whole brain functional network topology in Tourette’s syndrome
  publication-title: NeuroImage: Clinical
  doi: 10.1016/j.nicl.2019.101998
  contributor:
    fullname: Ramkiran
– year: 2021
  ident: B45
  article-title: Traditional Chinese medicine (TCM) therapy
  publication-title: J. Altern. Complement. Med
  contributor:
    fullname: Set
– volume: 11
  start-page: 1664
  year: 2020
  ident: B34
  article-title: What oes mmunology ave to o ith ormal rain evelopment and the athophysiology nderlying ourette yndrome and elated europsychiatric isorders?
  publication-title: Front. Neurol.
  doi: 10.3389/fneur.2020.567407
  contributor:
    fullname: Martino
– start-page: 1476
  year: 2022
  ident: B3
  article-title: Mispatterning and interneuron deficit in Tourette Syndrome basal ganglia organoids
  publication-title: Molecular psychiatry
  doi: 10.1038/s41380-022-01880-5
  contributor:
    fullname: Brady
– volume: 22
  start-page: 853
  ident: B23
  article-title: Immunological ysfunction in ourette yndrome and elated isorders
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22020853
  contributor:
    fullname: Hsu
– volume-title: Tourette syndrome and other tic disorders of childhood
  year: 2023
  ident: B36
  doi: 10.1016/B978-0-323-98817-9.00002-8
  contributor:
    fullname: Nilles
– start-page: 2162
  year: 2013
  ident: B39
  article-title: Genetic susceptibility and neurotransmitters in Tourette syndrome
  publication-title: Electronic
  contributor:
    fullname: Paschou
– volume: 7
  start-page: 2219
  year: 2018
  ident: B38
  article-title: Review of the evidence for the management of co-morbid Tic disorders in children and adolescents with attention deficit hyperactivity disorder
  publication-title: World J Clin Pediatr
  doi: 10.5409/wjcp.v7.i1.36
  contributor:
    fullname: Ogundele
– volume: 92
  start-page: 1526
  ident: B40
  article-title: Comprehensive systematic review summary: reatment of tics in people with Tourette syndrome and chronic tic disorders
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000007467
  contributor:
    fullname: Pringsheim
– volume: 302
  start-page: 1872
  year: 2023
  ident: B46
  article-title: Mechanism of Decoction in the treatment of colorectal cancer based on network pharmacology and experimental validation
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2022.115876
  contributor:
    fullname: Shang
– volume: 22
  start-page: 853
  ident: B22
  article-title: Immunological ysfunction in ourette yndrome and elated isorders
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22020853
  contributor:
    fullname: Hsu
– start-page: 1872
  year: 2020
  ident: B6
  article-title: The association between tic medication therapy and psychiatric comorbidities among patients with Tourette syndrome: national population-based study in Taiwan
  publication-title: Brain Dev
  doi: 10.1016/j.braindev.2020.01.002
  contributor:
    fullname: Chen
– start-page: 1179
  year: 2018
  ident: B26
  article-title: Antipsychotic-ssociated symptoms of tourette syndrome
  publication-title: A Syst Rev
  doi: 10.1007/s40263-018-0559-8
  contributor:
    fullname: Kim
– start-page: 1539
  volume-title: linical utility
  year: 2012
  ident: B17
  article-title: Diagnostic and statistical manual of mental disorders
  contributor:
    fullname: First
– start-page: 1473
  year: 2018
  ident: B20
  article-title: Tourette syndrome: clinical spectrum, mechanisms and personalized treatments
  doi: 10.1097/WCO.0000000000000575
  contributor:
    fullname: Hartmann
– volume: 57
  start-page: 667
  year: 2005
  ident: B28
  article-title: Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2004.12.004
  contributor:
    fullname: Leckman
– volume: 372
  start-page: 1873
  year: 2016
  ident: B29
  article-title: Transcriptome nalysis of the uman triatum in ourette yndrome
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2014.07.018
  contributor:
    fullname: Lennington
– volume: 31
  start-page: 1529
  year: 2011
  ident: B16
  article-title: Neurobiology of syndrome: current status and need for further investigation
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.0150-11.2011
  contributor:
    fullname: Felling
– volume-title: A eview of the urrent reatment of ourette yndrome
  year: 2020
  ident: B44
  contributor:
    fullname: Seideman Mf Fau - Seideman
– ident: B53
SSID ssj0000399364
Score 2.4025521
Snippet Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs...
Background Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of...
BackgroundYangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1397203
SubjectTerms immune infiltration
LASSO regression and SVM algorithm
network pharmacology
Pharmacology
tourette syndrome
Yangxue Xifeng decoction
SummonAdditionalLinks – databaseName: Directory of Open Access Journals at publisher websites
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELYQEwviTXjJSKgLhKaOk9gjr6pCAnUoUjfLMT7RJa1oGfrvuUvSNkVILGxREtnWd7bvO_nuM2NXyNfepXQi1MKnoVT0hPMoRGaQowfUGgQVOL-8pr03-TxMho2rvignrJIHroBr516BQ1odW4mxiPfIf6HjwUYg0lzXYtuRbgRT5R5MfjeVVZUMRmG6DZMPS_qfQt4S6RGLW7JqT1QK9v_GMn8mSza8T3eHbde0kd9Vw91lG77YY61-pTs9v-GDVRnV9Ia3eH-lSD3fZ73H0dRRruacj4HjsuVUdU-JOZ9TPir4DJunlB--0C_g-ZwXVYI4nzSaOmBv3afBQy-sr1AIHcYCs1DThV_adzKP69gmGExYZx1AlDgZo6cWDpTNlJReKoA08jLFqQVCufII0ceHbLMYF_6YcZ1q7yx0MkDWEWGrCrJUJvgEzirhA3a9gNNMKqUMgxEGgW9K8A2Bb2rwA3ZPiC__JJXr8gXa3tS2N3_ZPmCXC3sZXBV01GELP_6aGtI7lTH2EwXsqLLfsqtY4z6WZTpgas2ya2NZ_1KMPkrlbSo8JtZ08h-jP2VbhAgln3SiM7Y5-_zy58hwZvlFOZm_AWj2-2o
  priority: 102
  providerName: Directory of Open Access Journals
Title Discovery of key biomarkers in tourette syndrome by network pharmacology
URI https://www.ncbi.nlm.nih.gov/pubmed/39318779
https://www.proquest.com/docview/3109432030
https://pubmed.ncbi.nlm.nih.gov/PMC11420008
https://doaj.org/article/be8fc5483a4840ee974f1efa0f26b906
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbannYZtnUP71FoQNHL6sSRFVk6bu2KoECHHFqgN0HWxDXA6gRJesi_HynbbTLstJvhhySQlEhaHz8BHFO89lOpIHMro86V4Suyo5wig5o8oLUoucD56oee3KjL2_HtHui-FiaB9kM9GzS_7wfN7C5hKxf3YdjjxIbTqzOu_2TnNdyHfbLQrRw9rb_sc7VqK2QoA7NDXNx55v6UasABj-xPyOq8UCLr_1eE-TdQcsvzXLyA513IKL62Q3sJe7F5BSfTlnN6cyqun0qoVqfiREyf2Kg3hzA5n60C4zQ3Yo6CpqzginsG5SxXYtaINTXPcB_RcxeIeiOaFhwuFltNvYabi-_XZ5O8Oz4hD5QHrHPLh33ZOKoizWE_pkTCBx8Qi3FQJXlpGdD4yigVlUHURVSazAqlCWn7MJZv4KCZN_EdCKttDB5HFVLEUVCrBiutxnSFwRsZM_jSi9MtWpYMR9kFC98l4TsWvuuEn8E3lvjjm8xwnW7Ml79cp2dXR4OB0qnSK8pBY6S8B0cRfYFS17bQGXzu9eVoRvA2h2_i_GHlmOtUldRPkcHbVn-PXZWW1rCqshmYHc3ujGX3CRlhYt3uje79_3_6AZ6xHBhuMio-wsF6-RA_UUyzro_Sv4CjZMh_APH7-tI
link.rule.ids 230,315,730,783,787,867,888,2109,27937,27938,53805,53807
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwEN4p5QCXlnfNU8wwvVA7jizL1hEKnQBNJ4d06E0jC6nNlDqZxDmkv55dP9qkwwVuGsuWZO1Kuzv69hPAB_TXfglheai4k6HIqYR6FKJnUKAFVMpzSnAensjBqfh-lp5tgexyYWrQvi0mUfn7KionFzW2cnZlex1OrDcaHlL-Jxmv3j24jws2Ttei9HoHJqsrRZMjgzGY6vnZhSH2Ty4icnl4d0dWa4dquv6_-Zh3oZJrtudoF352o24gJ5fRsioie32H0PHff-sR7LTuKPvU1D-GLVc-gf1Rw2e9OmDj2_SsxQHbZ6NbpuvVUxh8mSwsYUBXbOoZbgeMsvkJ8DNfsEnJKmyeoESs40VgxYqVDfCczdaaeganR1_Hh4OwvZohtBhjVKGii8SU62cO9weTYpBirLHex6kVCXoA3PrcZLkQTuTey9gJiSrreW7ro0mXPIftclq6PWBKKmeN72cevZkYW819JkWKJW9Nzl0AHztB6VnDwKExciGx6lqsmsSqW7EG8JlkefMmsWfXD6bzc91Oti5c7i2GaokRGN86hzGV7ztvYs9loWIZwPtOEzSuNjpCMaWbLheaeFRFgv3EAbxoNOOmq0Th_phlKoB8Q2c2xrJZg5pQM3p3kn_5_5--gweD8fBYH387-fEKHtKcEKylH7-G7Wq-dG_Qd6qKt_VC-QPm3xwE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkRAXKO8ABSOhXmgemzhOfOyD1fJotYdWqsTBclybrqDZaJM9LL-emTza3YpTb1bi2I5n7JmRv_kM8An9tQvOTezL2Aqf51RCPfLRMyjQAkrpYkpwPj4RkzP-7Tw971GVdQ-rLE0xC8o_V0E5u2yxldWVCQecWDg9PqT8TzJeYXXhwvvwICXW9LVIvd2FyfIK3uXJYBwmQ1ddamIAjXlAbk883JPV26KWsv9_fuZtuOSa_Rk_gZ_DyDvYye9g2RSB-XuL1PFuv7YNj3u3lO13dZ7CPVs-g91px2u92mOnN2la9R7bZdMbxuvVc5gczWpDWNAVmzuG2wKjrH4C_ixqNitZg80TpIgN_AisWLGyA6Czaq2pF3A2_nJ6OPH7Kxp8g7FG40u6UEzaUWZxn9ApBivaaONclBqeoCcQG5frLOfc8tw5EVkuUHVdnJv2iNImL2GrnJf2NTAppDXajTKHXk2EreYuEzzFkjM6j60Hnwdhqapj4lAYwZBoVStaRaJVvWg9OCB5XtckFu32wXzxS_UTrgqbO4MhW6I5xrnWYmzlRtbpyMWikJHw4OOgDQpXHR2l6NLOl7UiPlWeYD-RB6867bjuKpG4T2aZ9CDf0JuNsWy-QW1omb0H6b-5-6cf4OH0aKx-fD35_hYe0ZQQumUUvYOtZrG0O-hCNcX7dq38A7F0HoQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+of+key+biomarkers+in+tourette+syndrome+by+network+pharmacology&rft.jtitle=Frontiers+in+pharmacology&rft.au=Zhao%2C+Jiali&rft.au=Bai%2C+Xiaohong&rft.date=2024-09-10&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=15&rft_id=info:doi/10.3389%2Ffphar.2024.1397203&rft.externalDBID=PMC11420008
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon